Homology Medicines, Inc.

Symbol: 0T6G.L

LSE

21.56

USD

Market price today

  • -0.7390

    P/E Ratio

  • -0.0083

    PEG Ratio

  • 283.62M

    MRK Cap

  • 0.00%

    DIV Yield

Homology Medicines, Inc. (0T6G-L) Financial Statements

On the chart you can see the default numbers in dynamics for Homology Medicines, Inc. (0T6G.L). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Homology Medicines, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

082.7175155.9
217.4
262.4
214.7
129.7
11.4

balance-sheet.row.short-term-investments

043.414147.5
0
208.6
176.5
78.1
0

balance-sheet.row.net-receivables

0000
0.4
0.4
0.8
0
0

balance-sheet.row.inventory

0000
0
0
0
0
0

balance-sheet.row.other-current-assets

01.3636
1.7
3.8
6.1
1.9
0.6

balance-sheet.row.total-current-assets

083.9181191.9
219.6
266.6
221.7
131.6
12

balance-sheet.row.property-plant-equipment-net

00.721.617.9
42.9
42.7
35.6
3.2
2

balance-sheet.row.goodwill

0000
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0

balance-sheet.row.long-term-investments

0025.82
1.3
1.3
0
0
0

balance-sheet.row.tax-assets

0221.600
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0000
0
0
-35.6
-3.2
-2

balance-sheet.row.total-non-current-assets

0222.247.519.8
44.2
44
35.6
3.2
2

balance-sheet.row.other-assets

0000
0
0
1.8
2.8
0.3

balance-sheet.row.total-assets

0306.1228.5211.7
263.7
310.6
259.1
137.5
14.2

balance-sheet.row.account-payables

03.21.12.4
4.7
2.6
15.7
2.5
0.9

balance-sheet.row.short-term-debt

01.31.60.2
2.5
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0

balance-sheet.row.long-term-debt-total

049.411.95
0
0
0
0
0

Deferred Revenue Non Current

0-104.401.2
32.1
30.1
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-

balance-sheet.row.other-current-liab

0718.711.4
9.8
9
6.8
6.3
1.2

balance-sheet.row.total-non-current-liabilities

0221.627.924.8
45.1
39.7
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

06.827.923.7
12.9
0
0
0
0

balance-sheet.row.total-liab

0233.150.542.1
67.7
52.1
22.5
8.9
2.1

balance-sheet.row.preferred-stock

0111.4111.4111.4
0
0
0
137.8
21.6

balance-sheet.row.common-stock

0000
0
0
0
0
0

balance-sheet.row.retained-earnings

0-542.1-429.1-424.1
-328.4
-199.7
-95.8
-40.2
-10.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-0.40
0
0.2
0
0
0

balance-sheet.row.other-total-stockholders-equity

0503.6496.1482.3
524.4
458
292.1
0.7
0.3

balance-sheet.row.total-stockholders-equity

073178169.7
196
258.5
196.4
98.3
11.7

balance-sheet.row.total-liabilities-and-stockholders-equity

0306.1228.5211.7
263.7
310.6
0
0
0

balance-sheet.row.minority-interest

0000
0
0
0
0
0

balance-sheet.row.total-equity

073178169.7
196
258.5
196.4
98.3
11.7

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-

Total Investments

043.4166.949.4
1.3
209.9
176.5
78.1
0

balance-sheet.row.total-debt

01.329.523.9
15.4
0
0
0
0

balance-sheet.row.net-debt

0-37.9-4.5-84.4
-202
-53.8
-38.2
-51.6
-11.4

Cash Flow Statement

The financial landscape of Homology Medicines, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

cash-flows.row.net-income

0-113-5-95.8
-128.7
-103.9
-55.6
-30
-8

cash-flows.row.depreciation-and-amortization

00.62.69.5
8.9
6.3
1.3
0.7
0.2

cash-flows.row.deferred-income-tax

00-19.2-38.8
-28.6
-24.7
0
0
0

cash-flows.row.stock-based-compensation

0013.117.2
13.2
7.6
2.6
0.3
0.2

cash-flows.row.change-in-working-capital

0-7.23.4-41.8
11.5
0.5
0
0
0

cash-flows.row.account-receivables

0000
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0

cash-flows.row.account-payables

02.1-1-2.5
2.5
-4.5
0
0
0

cash-flows.row.other-working-capital

0-9.34.3-39.3
9.1
4.9
0
0
0

cash-flows.row.other-non-cash-items

023.4-108.439.8
29.3
22.9
9.1
35.5
-0.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-0.2-1.3-2.4
-3.7
-21.8
-24.9
-2
-2

cash-flows.row.acquisitions-net

00.613048.4
-208.6
30
0
0
0

cash-flows.row.purchases-of-investments

0-73.2-157.5-97.4
-20
-286.4
0
0
0

cash-flows.row.sales-maturities-of-investments

0174.265.549
228.6
256.4
0
0
0

cash-flows.row.other-investing-activites

000-48.4
208.6
-30
-96.8
-79.6
-0.3

cash-flows.row.net-cash-used-for-investing-activites

0101.336.7-50.8
204.9
-51.8
-121.8
-81.5
-2.3

cash-flows.row.debt-repayment

0000
0
0
0
0
0

cash-flows.row.common-stock-issued

00.20.652.2
53.1
158.2
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0

cash-flows.row.other-financing-activites

000.652.2
53.1
158.2
151
115.2
0.4

cash-flows.row.net-cash-used-provided-by-financing-activities

00.20.652.2
53.1
158.2
151
115.2
0.4

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
1.8
0
21.8

cash-flows.row.net-change-in-cash

05.3-74.4-109
163.7
15.6
-11.6
40.2
11.4

cash-flows.row.cash-at-end-of-period

039.334108.4
217.4
53.8
40
51.6
11.4

cash-flows.row.cash-at-beginning-of-period

034108.4217.4
53.8
38.2
51.6
11.4
0

cash-flows.row.operating-cash-flow

0-96.2-113.7-109.8
-94.3
-91.4
-42.6
6.5
-8.5

cash-flows.row.capital-expenditure

0-0.2-1.3-2.4
-3.7
-21.8
-24.9
-2
-2

cash-flows.row.free-cash-flow

0-96.5-114.9-112.1
-98.1
-113.2
-67.5
4.5
-10.5

Income Statement Row

Homology Medicines, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of 0T6G.L is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

income-statement-row.row.total-revenue

01.23.234
2.7
1.7
5.3
0
0

income-statement-row.row.cost-of-revenue

00.62.69.5
100.4
89.4
47.9
21.4
0

income-statement-row.row.gross-profit

00.60.624.4
-97.7
-87.7
-42.6
-21.4
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0
0

income-statement-row.row.operating-expenses

092.7133.9120.4
124.1
105.3
17.3
9.2
8.1

income-statement-row.row.cost-and-expenses

093.3136.5129.9
133
111.6
65.2
30.5
8.1

income-statement-row.row.interest-income

05.63.20.2
1.6
6
4.3
0.5
0

income-statement-row.row.interest-expense

0000
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

05134.50.2
1.6
6
4.3
-0.3
2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0
0

income-statement-row.row.total-operating-expenses

05134.50.2
1.6
6
4.3
-0.3
2

income-statement-row.row.interest-expense

0000
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

00.62.69.5
8.9
6.3
1.3
0.7
0.2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-

income-statement-row.row.operating-income

0-92.1-133.3-95.9
-130.3
-109.9
-59.9
-29.7
-10

income-statement-row.row.income-before-tax

0-87.11.2-95.8
-128.7
-103.9
-55.6
-30
-8

income-statement-row.row.income-tax-expense

00.30.70.5
0
0
0
0
0

income-statement-row.row.net-income

0-113-5-95.8
-128.7
-103.9
-55.6
-30
-8

Frequently Asked Question

What is Homology Medicines, Inc. (0T6G.L) total assets?

Homology Medicines, Inc. (0T6G.L) total assets is 306119000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 2.827.

What is company free cash flow?

The free cash flow is -22.864.

What is enterprise net profit margin?

The net profit margin is 8.364.

What is firm total revenue?

The total revenue is 6.819.

What is Homology Medicines, Inc. (0T6G.L) net profit (net income)?

The net profit (net income) is -112961000.000.

What is firm total debt?

The total debt is 1318000.000.

What is operating expences number?

The operating expences are 92680000.000.

What is company cash figure?

Enretprise cash is 0.000.